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Expression profiling describes a group of technologies that
simultaneously assess the transcriptional activity of a large
number of genes. These technologies have ranged from
direct PCR amplification-based approaches, to cDNA or to
oligonucleotide two-dimensional arrays. Although originally
thought to be simply a way to multiplex a collection of indi-
vidual gene analyses (‘large-scale Northerns’), the reality is
that expression arrays produce a composite picture rich
with higher levels of biological information.
This complex picture is obtained through a statistical esti-
mate of the coordinate expression of a large number of
genetic elements relative to each other. Moreover, these
expression ‘cassettes’ do not require precision in the analy-
sis of individual gene expression, but rely on the ‘consen-
sus’ expression (either up or down) of large gene sets. This
primary principle of genome-wide expression profiling, that
data from comprehensive sets of gene probes give greater
biological information than the sum of the information from
individual genes, is exemplified in several papers recently
published on expression arrays and breast cancer.
Recent manuscripts by Sorlie et al. [1] and van’t Veer et al.
[2] appear to bear this principle out. Sorlie et al. investigated
78 breast cancers of different stages and histologic types,
and then pursued a second analysis in individuals treated
with unresectable T3/T4 breast cancer and doxorubicin
monotherapy [1]. Van’t Veer et al., however, examined 117
node-negative breast cancers, with 18 breast cancers from
women bearing germline BRCA1 mutations [2]. Sorlie et al.
interrogated their samples with a cDNA array containing
8102 genetic elements, and van’t Veer et al. employed a
25,000-element oligo-based array. In examining the collec-
tive results of these two studies, several truths emerge.
The first noteworthy point is that the tumors can be clus-
tered into groups in an unbiased manner by the composite
expression profiles. The dominant factor partitioning the
tumors is the estrogen receptor (ER) status. This has also
been observed by other workers [3]. Furthermore, in both
the studies of Sorlie et al. [1] and of van’t Veer et al. [2],
expression profile substructures could be discerned that
appear to be related to a molecular point of origin.
Commentary
Defining the galaxy of gene expression in breast cancer
Edison T Liu1 and Christos Sotiriou2
1Genome Institute of Singapore, Singapore
2Jules Bordet Institute, Brussels, Belgium
Correspondence: Edison T Liu, MD, Executive Director, Genome Institute of Singapore, 1 Science Park Road, #05-01 Science Park II, Singapore. 
Tel: +65 6827 5210; e-mail: gisliue@nus.edu.sg
Abstract
Recent reports detailing the expression profiles of primary breast cancer have pointed to the utility of
this approach in defining subclasses with distinct molecular configurations and clinical behaviour.
Some of the subclasses can be predicted by current molecular tests: estrogen receptor status, p53
staining, and HER-2 overexpression. Others, however, are novel subgroups and may represent distinct
cellular types. The results from two recent studies suggest common principles of classification by
expression profiling.  These principles are examined and the impact of these results on understanding
the biology and the clinical behaviour of breast tumors is explored.
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For example, Sorlie et al. showed that erbB2 positivity
appeared to be associated with a distinct expression
cluster of ER-negative tumors [1]. Moreover, ER-positive
tumors could be separated into expression groups that
ultimately correlated with the frequency of TP53 mutations
(luminal sybtype A with a 13% TP53 mutation rate, and
luminal subtype B and subtype C with 80% and 40%,
respectively, bearing TP53 mutations).
Van’t Veer et al. did not investigate subgroup structure
except to identify a set of 100 genes that could segregate
positive tumors from sporadic tumors [2]. Possibly
because of the small numbers of tumors studied, however,
no further clusters could be discerned beyond this level of
secondary structure.
An unresolved question arising from these studies is
whether these expression cassettes segregating with ER
status are due to the molecular/genetic origins of the
breast cancer or whether they reflect the cell lineage of
the tumor and are independent of the inducing
genes/oncogenes. To address this, our group, in conjunc-
tion with Dr Jeff Greene at the National Cancer Institute
(USA), examined the profiles of a number of mouse
mammary cancers arising from animals bearing various
onco-transgenes, using two different promoters targeting
different compartments in the mammary gland. We found
that the biochemical pathways served by the oncogenes
determined the ultimate tumor clusters, and that the differ-
ent promoters only altered the substructure and not the
major cluster determinants (KV Desai et al., manuscript
submitted). This work suggests that both the genetic
origins of a tumor and the cell lineage of origin can effec-
tively determine the downstream expression profile. The
genes of origin, however, may have more impact.
The second point of note is that these expression cas-
settes can provide a refined estimate of prognosis,
perhaps beyond those clinical indicators currently avail-
able to us. Sorlie et al. identified a luminal subgroup (sub-
group A) of ER-positive tumors associated with the best
outcome [1]. Interestingly, these tumors had the lowest
rate of TP53 mutations, suggesting that the ER status and
TP53 mutations significantly alter the expression profile of
a tumor and may be the major determinants of breast
cancer behavior [4].
The study of Sorlie et al. was not ideally suited to analyze
the prognosis given the extensive and heterogeneous
nature of the disease in these patients (T3/T4/N2). Van’t
Veer  et al. addressed this problem by investigating a
narrow subset of breast cancer patients: T1/T2, N0, and
M0, all younger than 55 years of age, treated only with
local regional therapies [2]. They found 231 genes signifi-
cantly associated with disease outcome as defined by the
presence of distant metastasis at the 5-year mark. Van’t
Veer et al. could then subsequently collapse this list to a
core set of 70 prognostic markers. These prognostic
genes appear to have functions involved in the cell cycle,
DNA repair, and chromosomal integrity.
Interestingly, van’t Veer et al. tested the ability of this array-
derived prognosis ‘expression profile’ to identify patients
who would benefit from adjuvant chemotherapy [2]. The
prognosis expression profile was then compared with
other standard guidelines for treatment of node-negative
breast cancer (National Institutes of Health and St Galen
consensus guidelines). Although the array-based expres-
sion profile could correctly identify patients who would
benefit from adjuvant chemotherapy, van’t Veer et al.
found that the greatest benefit was that this profile effec-
tively reduced by about 60% the fraction of women unnec-
essarily receiving adjuvant chemotherapy.
Van’t Veer et al. were concerned that their optimal 70-
gene prognostic profile did not include the known prog-
nostic markers such as HER-2, ER, cyclin D1 or
plasminogen activating inhibitor-1. However, other than
ER, the exclusion of the other known makers in the expres-
sion prognostic profile should actually not be a surprise.
For example, HER-2 overexpression is not common in
node-negative tumors (10–15%), and the impact on sur-
vival in this nonmetastatic form of breast cancer requires
studying large numbers of subjects [5]. Moreover, we
have assessed the impact of myc amplification and
implied overexpression in over 700 node-positive breast
cancer patients undergoing adjuvant chemotherapy, and
we found no prognostic impact or effect on the efficacy of
chemotherapy (ET Liu, unpublished results). The novel
gene list of Van’t Veer et al. may thus provide important
predictive information.
There is no doubt that much has been learned about the
genetic framework of breast cancer biology with the two
advanced studies of Sorlie et al. [1] and of van’t Veer et al.
[2]. The beauty of this genetic/genomic approach is that
one can amass large amounts of data but can immediately
telescope the attack to individual genes, an approach that
compares very favorably with interrogating the dots and
bands from two-dimensional protein gels or with differential
display experiments requiring significant downstream work.
However, it is fair to ask what impact this information may
have either on clinical practice or on our conceptualization
of the clinical disease. Cynics would question the current
significance. Indeed, in the study by Sorlie et al., the seg-
regation of good and bad prognostic groups in the ER-
positive tumors by the luminal classification could have
been accomplished using ER, the p53 sequence, and the
HER-2 status. Moreover, the gene profiling of the poor
outcome tumors in the van’t Veer et al. study has not pro-
vided any particularly new insights into why the tumors143
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behave badly. That some proliferation and repair genes
are upregulated is not novel. Expression arrays are cum-
bersome, expensive, and not specific, in that they also look
at the expression of nontumor-contaminating cells.
These concerns are understandable, although they were
the same types of criticisms directed towards bone marrow
transplantation and combination chemotherapy when both
those experimental concepts were originally launched. The
results of Sorlie et al. [1] and of van’t Veer et al. [2],
however, if applied and tested in clinical trials, may have
some interesting twists in terms of significance. For
example, there is now evidence that letrozole is more effec-
tive than tamoxifen in some forms of ER-positive breast
cancer defined by concurrent HER-2 or epidermal growth
factor receptor positivity [6]. Could this benefit be better
defined using markers that also determine the luminal
subtype B and subtype C? It also appears that ER-positive
tumors that are wild type at the TP53 locus, expressing
high levels of GATA binding protein-3, hepatocyte nuclear
factor 3 alpha, trefoil factor 3, and estrogen-regulated LIV-
1, possibly have the best prognosis and may be spared any
form of chemotherapy. Clinical trialists should quickly test
these novel findings in confirmatory trials.
Besides the advantages in gene discovery, these array
experiments are clearly changing how we view and
approach biological and clinical data. We predict that
these changes will be profound. This massively parallel
and highly comprehensive array technology has forced
laboratory scientists to adopt a statistical and population
approach to the data, and has forced clinical scientists to
seek novel and more biological approaches to their clini-
cal trials.
Reductionism has been the fundamental framework of our
scientific enterprise in both basic and clinical sectors:
study one gene/marker, hold all else constant, and assess
an outcome/read out. The subtext in both the Sorlie et al.
[1] and van’t Veer et al. [2] studies is that not one marker
or gene could correctly classify the tumors in terms of clin-
ical outcome. Instead, the composite analysis of multiple
genetic elements (from 70 to over 1000) may be neces-
sary to provide the needed resolution for tailored and per-
sonalized medicine. But this conceptual shift will require
us to overcome some old thinking and to address new
realities.
The statistical analysis of the data output from such com-
prehensive genomic approaches will be daunting. Experi-
mentally, it is not feasible to test the significance of each
gene in an array experiment using standard logistic regres-
sion. Thus, a move from assessing each gene as an inde-
pendent marker to developing robust approaches that
take into account the biological relationships between
markers might be necessary.
We should explore the development of a ‘consensus’
read-out of large marker profiles where the composite
information of multiple markers can be defined as a single
parameter. This has previously been attempted through
the use of ‘prognostic indices’ that mathematically
combine the predictive capabilities of many parameters
into one measure. The use of such indices that depict data
clusters with potential biological meaning may, however,
be necessary to rationally interpret array-based experi-
ments across clinical trials. For example, how does one
plan and interpret a trial to validate van’t Veer et al.’s
observations where the readout is not just one marker but
between 70 and 100 markers? This all suggests that new
statistical approaches and new study designs are neces-
sary to integrate genomic data in clinical trials.
Whole genomic expression profiling will need to be tested
in other settings in breast cancer (e.g. metastatic disease,
node-positive breast cancer, etc.) and in larger validation
studies, especially if survival is to be assessed. But the
integration of such quickly changing, highly complex tech-
nology with the more cumbersome phase III clinical trials
presents some serious experimental challenges. For
example, technology migration might cause a situation
where, every year that a clinical trial is accruing patients
and tissue samples, the molecular platform adopts a new,
and significantly better, format. Future clinical trialists will
face criticism either for analyzing their samples with piti-
fully outdated technology or for using normalization
schemes that are artificial at best. We suspect that a novel
study design taking into account progressive advances in
technology will be needed.
The problem that tumor marker studies currently have in
standardizing probes and scoring will worsen. Array
preparation has not been standardized. In addition, most
accessible expression array platforms still require refer-
ence RNA, and no common reference source has been
agreed upon. Even the format of the data fields is not con-
sistent from group to group. There will need to be some
common standards in the field so that trials data can be
interchangeable.
In truth, all these concerns are surmountable. But what we
are witnessing in molecular biology is what astronomers
have lived with for some time: that studying both the micro
and the macro is needed to gain the conceptual big
picture. One can learn much about the cosmos by study-
ing the rock samples from the moon and the rings of
Saturn, but some of the greatest wonders, such as the
origin of the stars, have been uncovered by observing the
galaxies in the universe. Happily, we are now at the begin-
nings of such galactic studies in biology.144
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